TR201903223T4 - Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. - Google Patents

Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. Download PDF

Info

Publication number
TR201903223T4
TR201903223T4 TR2019/03223T TR201903223T TR201903223T4 TR 201903223 T4 TR201903223 T4 TR 201903223T4 TR 2019/03223 T TR2019/03223 T TR 2019/03223T TR 201903223 T TR201903223 T TR 201903223T TR 201903223 T4 TR201903223 T4 TR 201903223T4
Authority
TR
Turkey
Prior art keywords
tuberculosis
vaccine
prevent reactivation
reactivation
muberculosis
Prior art date
Application number
TR2019/03223T
Other languages
English (en)
Inventor
Dietrich Jes
Andersen Peter
Vingsbo Lundberg Carina
Thi Kim Than Hoang Truc
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of TR201903223T4 publication Critical patent/TR201903223T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

Mevcut buluş, tüberküloz kompleksi mikroorganizmalarının (Mycobacterium tuberculosis., M.bovis, M.africanum) türlerinden kaynaklanan latent tüberküloz enfeksiyonunun reaktivasyonunu önlemek üzere latent olarak enfekte bireylere uygulanabilen bir aşıyı veya immünojenik bileşimi açıklar, Buluş, enfeksiyonun farklı aşamalarında temel olarak ifade edilen birçok M. muberculosis derive protein ve protein fragmanına bağlıdır. Buluş, bu polipeptidler, bunların immünolojik olarak aktif fragmanları ve aşılar gibi immünolojik bileşimlere yönelik bunları kodlayan genlerin kullanımı ile ilgilidir.
TR2019/03223T 2009-04-24 2010-04-23 Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. TR201903223T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900539 2009-04-24

Publications (1)

Publication Number Publication Date
TR201903223T4 true TR201903223T4 (tr) 2019-03-21

Family

ID=43010694

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03223T TR201903223T4 (tr) 2009-04-24 2010-04-23 Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.

Country Status (17)

Country Link
US (2) US9074001B2 (tr)
EP (1) EP2421557B1 (tr)
JP (2) JP5839361B2 (tr)
KR (2) KR20120014176A (tr)
CN (2) CN104107425B (tr)
AU (1) AU2010238943B9 (tr)
BR (1) BRPI1006452A2 (tr)
CA (1) CA2759583C (tr)
DK (1) DK2421557T3 (tr)
ES (1) ES2714383T3 (tr)
HK (2) HK1166018A1 (tr)
IL (1) IL215591A (tr)
MX (2) MX2011011186A (tr)
PL (1) PL2421557T3 (tr)
TR (1) TR201903223T4 (tr)
WO (1) WO2010121618A1 (tr)
ZA (1) ZA201108564B (tr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877426B1 (en) 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
KR20110060891A (ko) 2008-07-25 2011-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 신규한 조성물 및 방법
ES2602430T3 (es) * 2008-07-25 2017-02-21 Glaxosmithkline Biologicals S.A. Polipéptidos, polinucleótidos y composiciones para uso en el tratamiento de tuberculosis latente
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
JP6010463B2 (ja) 2010-01-27 2016-10-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変された結核抗原
LT2661253T (lt) * 2011-01-04 2017-05-25 Archivel Farma, Sl Liposomų kompozicija, tinkama tuberkuliozės gydymui arba prevencijai
RU2602771C2 (ru) 2012-01-12 2016-11-20 Арчивель Фарма, С.Л. Вакцина мбтк против астмы
EP2912056B1 (en) 2012-10-23 2020-02-12 Statens Serum Institut M. tuberculosis vaccines
CN110075287A (zh) 2013-03-15 2019-08-02 宾夕法尼亚大学理事会 用于结核病的预防或治疗的合成免疫原
CA2933817C (en) * 2013-12-16 2023-04-04 Statens Serum Institut Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
JP6605480B2 (ja) * 2014-01-09 2019-11-13 トランスジェン・ソシエテ・アノニム ヘテロオリゴマーマイコバクテリア抗原の融合物
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
CN104151433A (zh) * 2014-08-11 2014-11-19 兰州大学 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN104225591A (zh) * 2014-09-15 2014-12-24 兰州大学 一种免疫佐剂及含有该免疫佐剂的疫苗
EP3458088A2 (en) * 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
US20210290747A1 (en) * 2018-04-26 2021-09-23 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN110423279B (zh) * 2019-06-20 2021-07-27 扩增生物科技(北京)有限公司 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用
KR102577332B1 (ko) * 2021-12-29 2023-09-11 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
CN117777259A (zh) * 2024-02-23 2024-03-29 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法
CN1051234C (zh) * 1994-04-15 2000-04-12 焦安国 一种治疗结核病的药物
EP1741718A3 (en) 1995-06-07 2007-03-28 Sanofi Pasteur Inc. Expression of lipoproteins
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
AU779495B2 (en) 1999-07-13 2005-01-27 Statens Serum Institut Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosis esat-6 gene family
WO2001079274A2 (en) 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
GB0030368D0 (en) 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
CZ20031866A3 (cs) * 2001-01-08 2004-03-17 Isis Innovation Limited Způsob pro stanovení účinnosti léčení mykobakteriální infekce
EP1350839B1 (en) 2002-04-05 2010-06-02 Institut Pasteur Identification of virulence associated regions RD1 and RD5 enabling the development of improved vaccines of M. bovis BCG and M. microti
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2004067718A2 (en) 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
NZ555907A (en) * 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
NZ560468A (en) 2005-01-05 2010-05-28 Isis Innovation Compositions for immunizing against mycobacterium using Ag85A
EP1877426B1 (en) 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
JP5219808B2 (ja) 2005-06-23 2013-06-26 ステイテンス・セラム・インスティテュート 改良された結核ワクチン
WO2008000261A2 (en) * 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
ES2602430T3 (es) 2008-07-25 2017-02-21 Glaxosmithkline Biologicals S.A. Polipéptidos, polinucleótidos y composiciones para uso en el tratamiento de tuberculosis latente

Also Published As

Publication number Publication date
WO2010121618A1 (en) 2010-10-28
CA2759583A1 (en) 2010-10-28
JP2012524733A (ja) 2012-10-18
KR20170072366A (ko) 2017-06-26
AU2010238943A9 (en) 2015-10-15
CA2759583C (en) 2020-06-16
CN102413837A (zh) 2012-04-11
US20150093407A1 (en) 2015-04-02
US10519202B2 (en) 2019-12-31
DK2421557T3 (en) 2019-03-25
CN102413837B (zh) 2015-11-25
JP2015199771A (ja) 2015-11-12
JP6215260B2 (ja) 2017-10-18
HK1166018A1 (zh) 2012-10-19
KR20120014176A (ko) 2012-02-16
MX2011011186A (es) 2012-02-13
AU2010238943A1 (en) 2011-11-03
IL215591A0 (en) 2011-12-29
EP2421557B1 (en) 2018-12-05
HK1204549A1 (en) 2015-11-27
EP2421557A1 (en) 2012-02-29
JP5839361B2 (ja) 2016-01-06
AU2010238943B9 (en) 2015-10-15
US9074001B2 (en) 2015-07-07
CN104107425A (zh) 2014-10-22
AU2010238943B2 (en) 2015-09-17
ES2714383T3 (es) 2019-05-28
IL215591A (en) 2016-03-31
MX370744B (es) 2019-12-20
BRPI1006452A2 (pt) 2016-12-27
EP2421557A4 (en) 2013-03-13
CN104107425B (zh) 2018-07-17
US20120039925A1 (en) 2012-02-16
PL2421557T3 (pl) 2019-07-31
ZA201108564B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
TR201903223T4 (tr) Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
PH12014502250A1 (en) Mycoplasma hyopneumoniae vaccine
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
MX340830B (es) Vacuna neumococica y usos de la misma.
MX2011008791A (es) Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
BR112013009164A2 (pt) capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
EA201290956A1 (ru) Вакцина против вич
AR080111A1 (es) Metodos y composiciones de inmunizacion
CO6670521A2 (es) Vacuna y m´todos para reducir una infección por campylobacter
MX2016001695A (es) Composiciones inmunogenas de combinacion.
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
EP2521733A4 (en) HIGHLY CONSERVED HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) AND SMALL-VARIANT SEQUENCES THEREOF AS AIMS FOR VACCINATORY AND DIAGNOSIS USES
MX2018012270A (es) Novedosas formulaciones de vacuna neumococica.
TR201911128T4 (tr) Neısserıa menıngıtıdıs fhbp varyantı ve bunun aşılamaya yönelik kullanımı.
GB2515222A (en) Use of flagellin as a vaccine
WO2013084070A3 (en) Salmonella vaccine proteins
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2013173256A3 (en) New and improved influenza vaccines
MX368601B (es) Composicion inmunogenica contra la aeromonas hydrophila.
MX2014009022A (es) Virus de influenza c y vacuna.